Key indicators: single-crystal X-ray study; T = 100 K; mean (C-C) = 0.002 Å; disorder in main residue; R factor = 0.050; wR factor = 0.175; data-to-parameter ratio = 34.0.
In the title compound, C 20 H 21 ClN 2 O 2 , the ethyl 1H-benzimidazole-5-carboxylate ring system, excluding the methylene and methyl H atoms, is almost planar, with a maximum deviation of 0.055 (1) Å , and makes a dihedral angle of 40.63 (4) with the benzene ring. The sec-butyl group is disordered over two positions, with refined site occupancies of 0.855 (4) and 0.145 (4). In the crystal, molecules are linked into chains along [010] via intermolecular C-HÁ Á ÁO hydrogen bonds and are further interconnected by C-HÁ Á ÁCl interactions into two-dimensional networks parallel to (001). The crystal structure is further consolidated by C-HÁ Á Á interactions.
Related literature
For the synthesis of the title compound, see: Arumugam et al. (2010a,b,c) . For general background to and the therapeutic properties of benzimidazole derivatives, see: Bonfanti et al. (2008) ; Evans et al. (1997) ; Hori et al. (2002) ; Snow (2007) . For a related structure, see : Eltayeb et al. (2009) . For reference bond lengths, see: Allen et al. (1987) . For the stability of the temperature controller used in the data collection, see : Cosier & Glazer (1986) .
Experimental
Crystal data Table 1 Hydrogen-bond geometry (Å , ).
Cg1 is the centroid of the N1/C7/N2/C13/C8 ring. 
Data collection: APEX2 (Bruker, 2009 ); cell refinement: SAINT (Bruker, 2009 ); data reduction: SAINT; program(s) used to solve structure: SHELXTL (Sheldrick, 2008 ); program(s) used to refine structure: SHELXTL; molecular graphics: SHELXTL; software used to prepare material for publication: SHELXTL and PLATON (Spek, 2009 
Comment
Benzimidazole is an important pharmacophore in drug discovery and its derivatives have shown various therapeutic properties such as antiviral (Bonfanti et al., 2008) and anti-HIV-1 (Evans et al., 1997) activities. Benzimidazoles are used as biomimetics of guanine residues and selectively inhibit endothelial cell growth and suppress angiogenesis in vitro and in vivo (Hori et al., 2002) . In particular, substituted benzimidazole derivatives are also inhibitors of tyrosine kinase and are useful for inhibiting cell proliferation for the treatment of cancer (Snow et al., 2007) . In view of their importance, the crystal structure determination of the title compound was carried out and the results are presented here.
The molecular structure of the title compound is shown in Fig. 1 . The ethyl 1H-benzimidazole-5-carboxylate ring system (O1/O2/N1/N2/C7-C16), excluding methylene and methyl H atoms, is almost planar, with a maximum deviation of 0.055
(1) Å for atom O2, and makes a dihedral angle of 40.63 (4)° with the benzene (C1-C6) ring. The sec-butyl group is disordered over two positions with refined site-occupancies of 0.855 (4) and 0.145 (4). The bond lengths (Allen et al., 1987) and angles in the title compound are within normal ranges and comparable to those in a related crystal structure (Eltayeb et al., 2009 ).
In the crystal structure (Fig. 2) , the molecules are linked into one-dimensional chains along [010] via intermolecular C12-H12A···O2 hydrogen bonds and are further interconnected by C16-H16A···Cl1 interactions into two-dimensional networks parallel to (001). The crystal structure is further consolidated by C-H···Cg1 (Table 1) interactions; Cg1 is the centroid of the N1/C7/N2/C13/C8 ring.
Experimental
The title compound was synthesized using previously reported procedures (Arumugam et al., 2010a,b,c) . The crude product was recrystallized from ethyl acetate to yield the title compound as colourless crystals.
Refinement
All H atoms were positioned geometrically and refined using a riding model, with C-H = 0.93-0.98 Å and U iso (H) = xU eq (C), where x = 1.5 for methyl H and 1.2 for all other H atoms. A rotating-group model was applied for the methyl groups.
The sec-butyl group attached to the benzimidazole ring system is disordered over two positions, with refined site-occupancies of 0.855 (4) and 0.145 (4). Fig. 1 . The molecular structure of the title compound showing 50% probability displacement ellipsoids for non-H atoms and the atom-numbering scheme. Both disorder components are shown; atom labels with suffix A correspond to the major disorder component, while those with suffix B correspond to the minor disorder component. 
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